logo-loader
viewFaron Pharmaceuticals Ltd

Faron Pharma shares trial data at ASCO; updates on cancer trial recruitment

The poster presentation will show Faron’s precision cancer immunotherapy Clevegen was well-tolerated without ‘dose-limiting toxicities'

Faron Pharmaceuticals Ltd -

Faron Pharmaceuticals Oy (LON:FARN, First North:FARON) has said it will share previously published clinical data on its lead cancer drug at a leading industry conference.

In a stock market announcement flagging up the poster presentation it also updated on the progress of the next stage of its phase I/II trial.

The former first: Safety and efficacy results from the MATINS trial are to be shared at the American Society of Clinical Oncology annual meeting, which is being held as a virtual event this year.

The ASCO presentation will show Faron’s precision cancer immunotherapy Clevegen was well-tolerated without ‘dose-limiting toxicities’.

Immune cell activation was also seen along with downregulation of several checkpoint molecules. Clinical responses were observed.

“Despite the study patients’ very advanced stage of the disease and several lines of previous therapies, including PD-1 and CTLA-4 inhibitors, the early results from this dose finding stage of the MATINS study are very encouraging for single agent efficacy,” said Dr Markku Jalkanen, Faron’s chief executive.

A total of 30 people with advanced solid tumours who had exhausted all standard options took part in the first part of the phase I/II MATINS trial.

The company said recruitment for part II was underway with patients undeterred by the coronavirus outbreak. Being assessed at three different dose levels are groups with nine different cancers and three separate colorectal cohorts.

Of these, the lowest dose group has already started treatment, with the additional two colorectal cohorts set to join the trial by mid-summer 2020.

The company said it intends to present data from these test cohorts (10 patients at each dosing levels) to the US Food & Drug Administration at the end-of-phase II meeting “to obtain advice ahead of expansion into the pivotal part III stage of the trial”.

Quick facts: Faron Pharmaceuticals Ltd

Price: 297.5 GBX

AIM:FARN
Market: AIM
Market Cap: £139.23 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Faron Pharma CEO details new US Traumakine study and updates on Clevegen...

Faron Pharmaceuticals' (LON:FARN) Dr Markku Jalkanen speaks to Proactive London's Andrew Scott following a successful virtual R&D day this week. He also reports on the continued progress for two of its clinical stage programmes, Clevegen and Traumakine, including the just-announced...

2 weeks, 5 days ago

2 min read